Researchers initially investigated the Chang-Shuang-Li-Zhong powder mechanism through an integrated network pharmacology approach. Clinicians widely utilize this traditional Chinese medicine compound for managing ulcerative colitis, yet its molecular basis was previously unclear. To evaluate efficacy, researchers conducted experiments in both cellular and animal models. For instance, they activated RAW264.7 macrophages with LPS and induced colitis in mice using dextran sulfate sodium. Consequently, treatment with CSLZ significantly improved colon health by increasing length and reducing disease activity scores. In addition, the powder downregulated pro-inflammatory cytokines such as IL-1β and IL-6 at both mRNA and protein levels.

Understanding the Chang-Shuang-Li-Zhong powder mechanism in signaling

Moreover, the study identified the specific inhibition of protein phosphorylation as a primary action. Specifically, CSLZ suppresses the PI3K/Akt and MAPK pathways, including Akt, p38, ERK, and JNK. Therefore, these findings provide a scientific explanation for its clinical utility. Furthermore, this multi-target strategy positions the powder as a promising therapeutic agent for chronic intestinal inflammation. However, the researchers noted that further genetic validation is necessary to confirm these correlative findings.

Frequently Asked Questions

How does CSLZ powder reduce inflammation in the colon?

It inhibits the phosphorylation of key signaling proteins in the PI3K/Akt and MAPK pathways, which effectively lowers the production of pro-inflammatory cytokines like IL-1β and IL-6.

What animal model was used to validate the CSLZ mechanism?

The researchers employed a dextran sulfate sodium (DSS)-induced chronic colitis mouse model to observe improvements in colon length and disease activity.

Is CSLZ powder effective against other inflammatory bowel diseases?

While this study focused on ulcerative colitis, the multi-target anti-inflammatory pathways identified suggest potential relevance for other IBD types, though more research is needed.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Always consult a qualified physician for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhang G et al. Revealing the Mechanism of Chang-Shuang-Li-Zhong Powder in the Treatment of Ulcerative Colitis based on Network Pharmacology Approach. Comb Chem High Throughput Screen. 2026 Apr 06. doi: 10.2174/0113862073403084251212071505. PMID: 41944121.

2. Niu S, Zhang Y. Targeting the PI3K/Akt pathway for the treatment of ulcerative colitis: integrative regulatory features of traditional Chinese medicine. Front Pharmacol. 2025 Oct 9;16:1620138. doi: 10.3389/fphar.2025.1620138.

3. Wang M et al. Elucidating the Action Mechanism of Shenling Baizhu Powder in the Treatment of Ulcerative Colitis Based on Network Pharmacology and Experimental Validation. Comb Chem High Throughput Screen. 2025 Jun 13. doi: 10.2174/0113862073376167250527025217.